{
  "created_at": "Thu Jun 24 5:19:43 +0000 2021",
  "id_str": "1407922781162033152",
  "full_text": "In April we wrote that phase-three trials of Sinovac yielded an efficacy rate barely above the 50% threshold set by the WHO for covid-19 vaccines, but were good protection against severe disease and death https://t.co/DkNr6mlNKU",
  "display_text_range": [
    0,
    228
  ],
  "entities": {
    "hashtags": [],
    "symbols": [],
    "user_mentions": [],
    "urls": [
      {
        "url": "https://t.co/DkNr6mlNKU",
        "expanded_url": "https://econ.st/3dpAxNd",
        "display_url": "econ.st/3dpAxNd",
        "indices": [
          205,
          228
        ]
      }
    ]
  },
  "user": {
    "name": "The Economist",
    "screen_name": "TheEconomist",
    "profile_image_url_https": "https://pbs.twimg.com/profile_images/879361767914262528/HdRauDM-_normal.jpg"
  },
  "retweet_count": 33,
  "favorite_count": 92,
  "possibly_sensitive": false,
  "original_created_at": "Thu Jun 24 04:45:23 +0000 2021"
}